开始
Gilead Sciences, Inc.

GILD range bound, unlikely to break-out

由Fundamentals500提供
GILD

Remdesivir may help GILD breakout from multi-year range-bound pattern, however giving the limited income from it in the short-term, I would reckon we don't break out.
Fundamental AnalysisSupport and ResistanceTrend Analysis
Fundamentals500

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。